Back

Discussion.

26 August 2022 (16:10 - 16:15)
Organised by:
Congress Presentation Part of: New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice Lipid-Lowering Agents Open Access ESC Congress 2022

About the speaker

Photo
Professor Lina Badimon

Medical School, University of Vic-UCC and IRSI-CC, CIBERCV, Barcelona (Spain)

4 More presentations in this session

Presentation thumbnail
Introduction.
Professor L. Badimon (Barcelona, ES)
Slides Video
Presentation thumbnail
ASCVD & residual risk: recent clinical insights with icosapent ethyl.
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
A continuum of multifactorial benefits of icosapent ethyl.
Professor M. Back (Stockholm, SE)
Slides Video
Presentation thumbnail
Integrating icosapent ethyl in clinical practice: which patients will benefit?
Professor S. Verma (Toronto, CA)
Slides Video

Access the full session

Session thumbnail
New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 16:10 CET
You may be interested in
thumbnail
Congress Presentation
Effect of ethyl icosapent on lipid profile, inflammation, and cardiovascular events in real-world clinical practice: observational registry
24 April 2026
thumbnail
Congress Session
The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management
25 August 2023
thumbnail
Congress Session
Primary Care and Risk Factor Management 1
13 April 2023
thumbnail
Congress Presentation
Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources